BONE MARROW TRANSPLANTATION FOR LYMPHOMA PATIENTS WITH HIV/AIDS - A NARRATIVE REVIEW

This review aims to analyze the benefits of bone marrow transplantation (BMT) in patients positive for the Human Immunodeficiency Virus (HIV) with hematological malignancies and to understand the limitations of BMT in this scenario, as well as to obtain perspectives on the long-term therapeutic potential of the procedure. This is a literature review conducted by analyzing articles published between 2008 and 2024, written in English, obtained through the PubMed and BVS databases. The descriptors used are in accordance with the Health Sciences Descriptors System (DeCS), being: “Stem cell transplantation”, “Bone marrow transplantation”, “AIDS-related lymphoma” and “HIV-related lymphoma”. The reality of patients with HIV infection was revolutionized with the advent of Highly Active Antiretroviral Therapy (HAART), which increased their survival and reduced the prevalence of opportunistic diseases. However, the incidence of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) remains increased in HIV+ patients. In this sense, before the advent of HAART, stem cell transplantation was not feasible for HIV+ patients, due to the post-transplant course being characterized by multiple opportunistic infections and high rates of neoplastic relapse. After the emergence of HAART, mortality due to infections was reduced, but lymphoma control remains a challenge, due to drug interactions. Selected articles showed that HAART patients with HL and NHL undergoing chemotherapy followed by BMT had similar complete remission and survival rates to HIV-negative patients, with progression-free survival ranging from 49.5-85% and overall survival from 63.5-81%. This variation is due to different chemotherapy regimens, patient selection criteria, and viral load. Allogeneic hematopoietic stem cell transplantation in HIV+, despite the not so vast experimental basis in the literature, can be performed safely and lead to long-lasting remissions, as well as having a remote potential to eradicate HIV infection, with 6 cases already reported in the literature. Furthermore, transplantation-related toxicity, event-free survival, relapse rate, and overall survival of HIV+ patients were similar to those of HIV-negative patients, but there is a higher risk of infection. The review pointed out clear benefits of allogeneic hematopoietic stem cell transplantation in HIV-positive patients, significantly increasing the overall survival of this group, with results similar to those of HIV-negative pat